RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.18% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-29 was 2.90%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-09-30 was 2.13%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 1.70%, a 5.56% decline year-over-year.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.60%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.18% 10-Q · filed 2026-08-06 | ||||
| 2022-09-29 | 2.90% 10-K · filed 2023-03-23 | ||||
| 2022-09-20 | 9.99% 10-K · filed 2023-03-23 | ||||
| 2022-03-28 | 2.55% 10-Q · filed 2022-05-05 | 2.55% 10-K · filed 2023-03-23 | |||
| 2021-07-16 | 0.48% 10-Q · filed 2021-11-12 | ||||
| 2021-07-12 | 0.43% 10-Q · filed 2021-11-12 | ||||
| 2021-06-25 | 0.48% 10-Q · filed 2021-08-10 | 0.43% 10-Q · filed 2021-11-12 | |||
| 2021-06-18 | 0.47% 10-Q · filed 2021-08-10 | 0.47% 10-Q · filed 2021-11-12 | |||
| 2021-02-18 | 0.75% 10-K · filed 2023-03-23 | ||||
| 2021-01-06 | 0.59% 10-K · filed 2023-03-23 | ||||
| 2017-09-30 | 2.13% 10-Q · filed 2017-11-14 | ||||
| 2015-12-31 | 1.70% 10-Q · filed 2017-02-10 | ||||
| 2015-09-30 | 1.70% 10-Q · filed 2015-11-06 | ||||
| 2015-03-31 | 1.60% 10-Q · filed 2015-05-15 | ||||
| 2014-09-30 | 1.80% 10-Q · filed 2015-11-06 | ||||
| 2013-12-31 | 1.40% 10-Q · filed 2015-02-13 | 1.40% 10-Q · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |